Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
Thomas JD, Yurkovetskiy AV, Yin M, Bodyak ND, Gumerov DR, Tang S, Kelleher E, Jones BD, Protopopova M, Qin L, Uttard A, Demady DR, Lowinger TB. Thomas JD, et al. Among authors: lowinger tb. Bioorg Med Chem Lett. 2022 Sep 15;72:128876. doi: 10.1016/j.bmcl.2022.128876. Epub 2022 Jul 3. Bioorg Med Chem Lett. 2022. PMID: 35788036
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV, Bodyak ND, Yin M, Thomas JD, Clardy SM, Conlon PR, Stevenson CA, Uttard A, Qin L, Gumerov DR, Ter-Ovanesyan E, Bu C, Johnson AJ, Gurijala VR, McGillicuddy D, DeVit MJ, Poling LL, Protopopova M, Xu L, Zhang Q, Park PU, Bergstrom DA, Lowinger TB. Yurkovetskiy AV, et al. Among authors: lowinger tb. Mol Cancer Ther. 2021 May;20(5):885-895. doi: 10.1158/1535-7163.MCT-20-0166. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722857
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND, Mosher R, Yurkovetskiy AV, Yin M, Bu C, Conlon PR, Demady DR, DeVit MJ, Gumerov DR, Gurijala VR, Lee W, McGillicuddy D, Park PU, Poling LL, Protopova M, Qin L, Stevenson CA, Ter-Ovanesyan E, Uttard A, Xiao D, Xu J, Xu L, Bergstrom DA, Lowinger TB. Bodyak ND, et al. Among authors: lowinger tb. Mol Cancer Ther. 2021 May;20(5):896-905. doi: 10.1158/1535-7163.MCT-20-0183. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722858
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
Wickens P, Kluender H, Dixon J, Brennan C, Achebe F, Bacchiocchi A, Bankston D, Bierer D, Brands M, Braun D, Brown MS, Chuang CY, Dumas J, Enyedy I, Hofilena G, Hong Z, Housley T, Jones B, Khire U, Kreiman C, Kumarasinghe E, Lowinger T, Ott-Morgan R, Perkins L, Phillips B, Schoenleber R, Scott WJ, Sheeler R, Redman A, Sun X, Taylor I, Wang L, Wilhelm S, Zhang X, Zhang M, Sullivan E, Carter C, Miglarese M, Levy J. Wickens P, et al. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4378-81. doi: 10.1016/j.bmcl.2007.02.075. Epub 2007 Mar 3. Bioorg Med Chem Lett. 2007. PMID: 17574417
Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1.
Murata T, Shimada M, Sakakibara S, Yoshino T, Kadono H, Masuda T, Shimazaki M, Shintani T, Fuchikami K, Sakai K, Inbe H, Takeshita K, Niki T, Umeda M, Bacon KB, Ziegelbauer KB, Lowinger TB. Murata T, et al. Among authors: lowinger tb. Bioorg Med Chem Lett. 2003 Mar 10;13(5):913-8. doi: 10.1016/s0960-894x(02)01046-6. Bioorg Med Chem Lett. 2003. PMID: 12617920
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J, Hatoum-Mokdad H, Sibley R, Riedl B, Scott WJ, Monahan MK, Lowinger TB, Brennan C, Natero R, Turner T, Johnson JS, Schoenleber R, Bhargava A, Wilhelm SM, Housley TJ, Ranges GE, Shrikhande A. Dumas J, et al. Among authors: lowinger tb. Bioorg Med Chem Lett. 2000 Sep 18;10(18):2051-4. doi: 10.1016/s0960-894x(00)00272-9. Bioorg Med Chem Lett. 2000. PMID: 10999468
29 results